19552634 |
Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation
Tomlinson, W,
Wissing, BM,
Nilsson, L,
VAN Giezen, JJ,
Giordanetto, F,
Berntsson, P,
Greasley, PJ
|
J. Thromb. Haemost. |
2009 |
26194851 |
Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information
Abdelrahman, A,
Baqi, Y,
Sabbadin, D,
Paoletta, S,
Zhao, Q,
Moro, S,
Hinz, S,
Straßburger, J,
von Kügelgen, I,
Katritch, V,
Jacobson, KA,
Müller, CE,
Hoffmann, K,
Stevens, RC
|
J. Comput. Aided Mol. Des. |
2015 |
24414167 |
Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1
Ewart, L,
VAN Giezen, JJ,
Summers, C,
Armstrong, D,
Sidaway, JE,
Nylander, S
|
J. Cardiovasc. Pharmacol. Ther. |
2014 |
27694321 |
Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor
Conibear, A,
Mundell, SJ,
Mumford, A,
Aungraheeta, R,
Butler, M,
Nylander, S,
Kelly, E
|
Blood |
2016 |
23890048 |
Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism
Nilsson, RG,
Asztély, AK,
Nylander, S,
Löfgren, L,
Femia, EA,
Berntsson, P,
Scavone, M,
Nelander, K,
Cattaneo, M
|
J. Thromb. Haemost. |
2013 |